References
- Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34 + progenitor cells. Cancer Res 2007;67:746–755.
- Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69:7347–7356.
- List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–1465.
- Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010; 28:4919–4925.
- Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011;117:1828–1833.
- Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood 2011;118:523–528.
- List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndrome. N Engl J Med 2005;352:549–557.
- Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86–93.
- Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011;117:1828–1833.
- Wei P. Thrombopoietin factors. Cancer Treat Res 2011;157:75–93.
- Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010;28:437–444.
- Erickson-Miller CL, Kirchner J, Aivado M, et al. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010;34:1224–1231.
- Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009;114:3899–3908.
- Mavroudi I, Pyrovolaki K, Pavlaki K. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res 2011;35:323–328.
- Bennett JM, Catovsky D, Daniel MT. Proposal for the classification of myelodyplastic syndromes. Br J Haematol 1982;51:189–199.
- Bennett JM, Catovsky D, Daniel MT. Proposal for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451–458.
- Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Eng J Med 2007;357:2237–2247.
- Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenia purpura: a randomized, double-blind, placebo-controlled trial. Lancet 2009;373:641–648.
- Chou FS, Mulloy J. The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis. J Cell Biochem 2011;112: 1491–1498.
- Sitnicka E, Lin N, Priestley GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996;87:4998–5005.
- Wetzler M, Baer M, Bernstein SH, et al. Expression of c-mpl mRNA, the receptor of thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J Clin Oncol 1997;15:2262–2268.
- Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction differentiation. Blood 2012;120:386–394.